These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 19182242)

  • 41. Chromosome imbalances in oligodendroglial tumors detected by comparative genomic hybridization.
    Bourdon V; Plessis G; Chapon F; Guarnieri J; Derlon JM; Jonveaux P
    Ann Genet; 2004; 47(2):105-11. PubMed ID: 15183742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].
    Born PW; Broholm H; Laursen H
    Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component.
    Walker C; du Plessis DG; Fildes D; Haylock B; Husband D; Jenkinson MD; Joyce KA; Broome J; Kopitski K; Prosser J; Smith T; Vinjamuri S; Warnke PC
    Clin Cancer Res; 2004 Nov; 10(21):7182-91. PubMed ID: 15534091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oligodendrogliomas: new insights from the genetics and perspectives.
    Alentorn A; Sanson M; Idbaih A
    Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
    Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
    Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
    Cairncross G; Jenkins R
    Cancer J; 2008; 14(6):352-7. PubMed ID: 19060598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Oligodendrogliomas: their morphological characteristics and molecular alterations].
    Carrato-Monino C; Ariza A
    Rev Neurol; 2007 Mar 16-31; 44(6):353-9. PubMed ID: 17385172
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors.
    Trost D; Ehrler M; Fimmers R; Felsberg J; Sabel MC; Kirsch L; Schramm J; Wiestler OD; Reifenberger G; Weber RG
    Int J Cancer; 2007 Jun; 120(11):2368-76. PubMed ID: 17285580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
    Anderson MD; Gilbert MR
    Oncology (Williston Park); 2013 Apr; 27(4):315-20, 322. PubMed ID: 23781695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advances in the biology and treatment of oligodendrogliomas.
    van den Bent MJ
    Curr Opin Neurol; 2004 Dec; 17(6):675-80. PubMed ID: 15542975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New perspectives for the diagnosis and treatment of oligodendroglioma.
    van den Bent MJ
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):348-56. PubMed ID: 12113102
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular pathology and clinical characteristics of oligodendroglial neoplasms.
    Walker C; du Plessis DG; Joyce KA; Fildes D; Gee A; Haylock B; Husband D; Smith T; Broome J; Warnke PC
    Ann Neurol; 2005 Jun; 57(6):855-65. PubMed ID: 15929038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. alpha-Internexin expression identifies 1p19q codeleted gliomas.
    Ducray F; Crinière E; Idbaih A; Mokhtari K; Marie Y; Paris S; Navarro S; Laigle-Donadey F; Dehais C; Thillet J; Hoang-Xuan K; Delattre JY; Sanson M
    Neurology; 2009 Jan; 72(2):156-61. PubMed ID: 19139367
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Towards a molecular classification of gliomas].
    Hoang-Xuan K; Idbaih A; Mokhtari K; Sanson M
    Bull Cancer; 2005 Apr; 92(4):310-6. PubMed ID: 15888387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in diagnosis and management of oligodendroglioma.
    Hussein MR; Baidas S
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):520-8. PubMed ID: 12382520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FISH 1p/19q deletion/imbalance for molecular subclassification of glioblastoma.
    Nagasaka T; Gunji M; Hosokai N; Hayashi K; Ikeda H; Ito M; Inao S
    Brain Tumor Pathol; 2007; 24(1):1-5. PubMed ID: 18095137
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Influence of molecular-genetic factors on prognosis in patients with oligodendroglial tumors].
    Absaliamova OV; Korshunov AG; Loshakov VA; Kobiakov GL; Golanov AV; Urakov SV; Amanov RD; Lichinitser MR
    Zh Vopr Neirokhir Im N N Burdenko; 2009; (1):17-23; discussion 23-4. PubMed ID: 19507310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response.
    Jaeckle KA; Ballman KV; Rao RD; Jenkins RB; Buckner JC
    J Clin Oncol; 2006 Mar; 24(8):1246-52. PubMed ID: 16525179
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemotherapy of oligodendroglial tumours: current developments.
    van den Bent MJ
    Forum (Genova); 2000; 10(2):108-18. PubMed ID: 10875973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New treatment paradigm for patients with anaplastic oligodendroglial tumors.
    Polivka J; Polivka J; Rohan V; Topolcan O
    Anticancer Res; 2014 Apr; 34(4):1587-94. PubMed ID: 24692686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.